CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include 15-cubic foot and 30-cubic foot V-shell blenders, a 43-station high speed tablet press, high speed encapsulation and a 40-inch solvent-capable coating pan. The additional equipment train will allow for increased clinical batch sizes in support of growing client demand. The additional equipment will allow CoreRx scientists to manufacture batch sizes of up to one million solid dosage units per day.
CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50 companies. The Tampa Bay Business Journal’s Fast 50 is a list of the fastest growing privately held companies in Tampa Bay over a span of three years. Last year, CoreRx was recognized as the 6th fastest growing company in the Tampa Bay region.
CoreRx has appointed William Beck as Director, Business Development, covering the Northeast. Mr. Beck will be responsible for all business development activities in support of the company’s strategic growth and development plans for this region.
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include the OYSTAR Manesty FLEXITAB, A fully automated, single station tablet press with a multi-layer tablet function, giving it the unique capacity to produce three-layer tablets using a minimal amount of material. Its variable punch displacement and dwell time can be set to simulate compression on any rotary press using compression forces up to100kN.
Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan given four year appointments to begin teaching this inaugural school year
(Tampa, FL; 15 August 2011) – CoreRx, a leader in early drug development services, today announced the appointments of Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan to the Faculty of the School of Pharmacy at the University of South Florida, as Assistant Professors.
LARGO, FL (Nov. 30, 2010) – Pharmaceutical manufacturer CoreRx will soon add 55 high-wage jobs to Pinellas County, Florida, while retaining its current 16 Tampa Bay employees. The new jobs result from a planned expansion that also necessitates a new, larger location.
CoreRx continues to grow in 2010, providing unsurpassed contract pharmaceutical development services to the pharma & biotech industries. This is more evident with the latest announcement of the Tampa Bay Business Journal announcement of the Fast 50 nominees.
Pharmaceutical development provider CoreRx announced today it will be hiring top candidates in the areas of preformulation and formulation development. CoreRx will also increase headcount in analytical, manufacturing and client logistics, strengthening their commitment to customer first service excellence.
SoluBest, Ltd, today announced an agreement to license its proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs to CoreRx, Inc., an innovative contract formulation company. SoluBest’s Solumer™ technology is extremely versatile, as it can be applied to a wide range of pharmaceuticals. The license agreement will provide CoreRx with access to Solumer™ technology and the rights to apply the technology to client’s drug candidates currently in clinical development.